Advarra’s Post

India's clinical trials sector is poised for exponential growth, driven by its diverse patient pool and efficient infrastructure. Despite regulatory hurdles, the industry is projected to reach $23 billion by 2027, ranking third globally. Indian Society for Clinical Research (ISCR) acts as a vital catalyst for ethical clinical research, not only within the Indian clinical research ecosystem but across the globe, guiding the industry towards improved patient outcomes and groundbreaking advancements. At the 17th Annual Conference of the Indian Society for Clinical Research (ISCR), themed 'Transformations in Clinical Research for Better Patient Outcomes,' experts convened to discuss and innovate advanced research methodologies and foster collaboration. As proud communications partners for ISCR, Jajabor Brand Consultancy crafted the event's narrative, spotlighting the crucial role of clinical research in healthcare. Together, we're committed to driving impactful conversations and propelling healthcare endeavours forward. #ChangeTheDialogue #ClinicalResearch #ISCRAnnualConference #HealthcareInnovation #Jajabor #GrowthHackers #Storytelling #StoryTellers #JajaborBrandConsultancy #ImpactDrivenDialogues

Our journey is fueled by a belief in the power of medical innovation to transform lives. Clinical trials are the cornerstone of this journey, where hope meets reality, and breakthroughs become therapies. With 321 active clinical trials, the highest of any company in the nation, India plays a crucial role in this endeavour and is instrumental in driving forward our global research initiatives. Each clinical trial represents a chance to bring hope to patients, offering the possibility of better health and brighter futures. We aim to accelerate the pace of discovery and bring life-changing therapies to patients faster. #ReimaginingMedicine #ClincialTrialsDay

The Anjani Mashelkar Prize #winners are making waves globally with their impactful work. The recent article of iBreastExam in the world's leading medical journal, 'The Lancet Global Health', sheds light on the remarkable performance of iBreastExam in breast lesion detection among high-risk and symptomatic Nigerian women. Read more: https://lnkd.in/d7_JatpT The results are truly outstanding - for any breast finding, iBreastExam exhibited significantly better sensitivity than clinical breast examination, while clinical breast examination showed significantly better specificity. This is a testament to the inclusive innovation's power to transcend borders and positively impact not only India but the world at large. From India to the global stage, Anjani Mashelkar Prize champions continue to redefine healthcare norms. Kudos to the iBreastExam team for their dedication to creating innovations that leave a lasting impact on global health. Know more about iBreastExam: https://lnkd.in/dfqtNdfv #AnjaniMashelkarPrize #inclusiveinnovation #globalimpact #healthcareinnovation iBreastExam

if more divisions of Regulators/ Experts according to therapeutic area or region-wise are involved in the approval process; work can be done faster

With 500,000 people awaiting treatment for drug-resistant #Tuberculosis (TB), the World #AMR Awareness Week is also an important opportunity to call for a more successful global TB response! TB #Research & #Innovation must be accelerated, and this can hardly be done without the creation of innovative partnerships such as UNITE4TB and PAN-TB. Last week's #UnionConf2023 was an excellent showcase of the progress and outcomes from these two initiatives with a dedicated joint satellite session. The main takeaways are summarised in this news piece: https://lnkd.in/ebrDFRYY #EndTB #WAAW2023 #StrongerTogether

The Indian diagnostics industry at crossroads, marked by both opportunities and challenges The diagnostic industry in India encounters formidable challenges rooted in a dual issue of insufficient skilled personnel and a widespread lack of awareness. The sector's fragmentation, encompassing large chains, hospital laboratories, and independent testing centres, contributes to a diverse landscape. However, the absence of stringent regulations has led to the emergence of unaccredited centres, raising concerns about the quality of diagnostic services provided. #diagnostics | #industry | #fragmentation | #stringent | #healthnews Redcliffe Labs Dr Sohini Sengupta Prabhat Prakash Read more:

Join us for a live panel discussion titled “The State of Online Medicine Delivery in Bangladesh”, organized by the Center for Enterprise and Society (CES), ULAB, in collaboration with Future Startup. Discover how online medicine delivery, a $59 million market, is revolutionizing healthcare industry in post-COVID timeline. Learn from industry leaders about the driving forces, role of health tech, and future opportunities.

Our proprietary portfolio in #rarediseases continues to progress and Eleva is exploring a global strategy to evaluate these programs in patients starting 2025 🇩🇪 🇮🇳.   C3 glomerulopathy, or #C3G for short, is one of the complement disorders Eleva is targeting. Since the prevalence of C3G in India is considered much higher compared to other regions, local KOLs have gathered considerable expertise in treating patients affected by the condition.   🛫 We are proud to have made first connections in India in an early effort to understand the clinical network serving these patients. Our growing clinical development team led by Karin Heidenreich and Dr. Martin Bauer, MD has recently spent an extended period in the region to introduce Eleva's potential solution to KOLs and medical practitioners.   🗓 We are equally proud that one of the top KOLs from India, Prof. Dr. Dinesh Khullar, joined our team and fellow KOL and complement expert Prof. Dr. Peter Zipfel for our clinical development webcast. Our guest speakers shared their knowledge and expertise on #factorH, #C3G, the #clinicalpractice in India, and #complementdisorders at large. To watch the replay, please go to: https://lnkd.in/eRJmEFDm   Prof. Khullar reminded us that even a rare disease such as C3G statistically affects more than 1 million patients in a country of India’s size. We also learned that access to approved treatment options in C3G, often taken for granted in the western world, is not such an easy task in India. We thank both speakers and all participants for joining us in this first webcast session! www.elevabiologics.com Oviya MedSafe, Dr Vijay Venkatraman Janarthanan, KarthikaPandi Jeyachandran, Deepti Goel, Fabienne Zeitter

🚀 Ready to launch a successful clinical trial choosing the right sites? Introducing NexTrial, the tool that elevates your trial by choosing optimal sites tailored to your unique objectives.:   ✅ Analyzes hundreds of data points to identify high-success rate sites ✅ Utilizes past performance and epidemiological data for optimal site ranking ✅ Customize parameters to fit your unique trial needs   Interested in mastering site feasibility? Dive into our comprehensive guide: "Mastering Site Feasibility in Clinical Trials: A Guide for Successful Site Selection." Gain valuable insights and strategies to ensure you choose the best sites for your clinical trials ➡️ https://lnkd.in/dGr5_CT9   #ClinicalTrials #SiteSelection #NexTrial #PrecisionMedicine #ClinicalResearch #Innovation #MachineLearning

great to meet like minded professionals across the department in the clinical research #clinicalresearch and fantastic panel discussions with very great insight into recent trends and advancement in the regulatory space #iscr #clinicaldevelopment #clinicaldatamanagement #medicaldevices #medicalwriting #clinicaloperations #cra #clinicalstudies